array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2748) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(80) "Nasal Polyposis Drugs Market Research Report 2023-2087 – Bosnian National Team" ["snippet_en"]=> string(262) "According to a recent Factor survey, the global nasal polyposis drug is poised to capture significant market opportunities from a variety of end-use industries. This study of the global Nasal Polyposis Drug market provides a comprehensive analysis of the various" ["url"]=> string(100) "https://bnm.ba/news/marktforschungsbericht-fuer-medikamente-gegen-nasenpolyposis-2023-2087-2/503670/" ["image_url"]=> NULL ["source"]=> string(6) "bnm.ba" ["publication_date"]=> string(10) "2024-11-09" ["categories"]=> array(3) { [0]=> string(17) "Academic Research" [1]=> string(19) "New Revenue Streams" [2]=> string(15) "Market Movement" } } [1]=> array(7) { ["title_en"]=> string(74) "Harnessing Community Insights to Shape the Future of Hemophilia B Research" ["snippet_en"]=> string(106) "Discover how Regeneron leverages community insights and collaboration to advance research in Hemophilia B." ["url"]=> string(101) "https://hemaware.org/community-pulse/harnessing-community-insights-shape-future-hemophilia-b-research" ["image_url"]=> string(78) "https://images.businessradar.com/articles/ae6b18e1-a339-4c00-8dc3-0810666f5333" ["source"]=> string(12) "hemaware.org" ["publication_date"]=> string(10) "2024-10-04" ["categories"]=> array(2) { [0]=> string(17) "Academic Research" [1]=> string(13) "Collaboration" } } [2]=> array(7) { ["title_en"]=> string(198) "Intellia Therapeutics to Present Latest Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis on the 2024 AHA Scientific Sessions" ["snippet_en"]=> string(134) "Latest data to be presented will include biomarkers of disease progression and functional capability from the continuing Phase 1 study" ["url"]=> string(220) "https://todaysstocks.com/intellia-therapeutics-to-present-latest-clinical-data-from-the-phase-1-study-of-nexiguran-ziclumeran-nex-z-for-the-treatment-of-transthyretin-attr-amyloidosis-on-the-2024-aha-scientific-sessions/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/7c90f88d-6ab9-4428-abc7-9c41a159fbaa" ["source"]=> string(16) "todaysstocks.com" ["publication_date"]=> string(10) "2024-10-01" ["categories"]=> array(4) { [0]=> string(17) "Academic Research" [1]=> string(13) "Collaboration" [2]=> string(16) "Customer Privacy" [3]=> string(13) "Data Security" } } [3]=> array(7) { ["title_en"]=> string(79) "Students from Erbaa will represent Turkey in the Project Competition in America" ["snippet_en"]=> string(158) "High school students in Erbaa achieved great success by coming 3rd in Türkiye in the research projects competition held in the Technological Design category." ["url"]=> string(101) "https://www.kelkitgazetesi.com/erbaali-ogrencilerin-basarisi-amerikada-proje-yarismasina-katilacaklar" ["image_url"]=> NULL ["source"]=> string(18) "kelkitgazetesi.com" ["publication_date"]=> string(10) "2024-09-18" ["categories"]=> array(2) { [0]=> string(17) "Academic Research" [1]=> string(11) "Competition" } } [4]=> array(7) { ["title_en"]=> string(94) "Irish student claims International Swiss Talent Forum award at EU Contest for Young Scientists" ["snippet_en"]=> string(294) "SciFest STEM winner 2023, Jack Shannon won the International Swiss Talent Forum Award at the EU Contest for Young Scientists (EUCYS) 2024 in Katowice, Poland. Shannon represented Ireland at the Regeneron International Science and Engineering Fair( ISEF) in Los Angeles in May and was one of two" ["url"]=> string(122) "https://www.techcentral.ie/irish-student-claims-international-swiss-talent-forum-award-at-eu-contest-for-young-scientists/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/0d78f3d0-d4a1-4ccd-9de7-e2a8015f1331" ["source"]=> string(14) "techcentral.ie" ["publication_date"]=> string(10) "2024-09-17" ["categories"]=> array(3) { [0]=> string(17) "Academic Research" [1]=> string(5) "Award" [2]=> string(5) "Event" } } [5]=> array(7) { ["title_en"]=> string(103) "University of Natural Sciences - National University Ho Chi Minh City welcomes more than 4,100 students" ["snippet_en"]=> string(169) "GD&TD - More than 4,100 new students attended the opening ceremony of the University of Natural Sciences (National University of Ho Chi Minh City) held on September 15." ["url"]=> string(110) "https://giaoducthoidai.vn/truong-dh-khoa-hoc-tu-nhien-dh-quoc-gia-tphcm-don-hon-4100-sinh-vien-post701001.html" ["image_url"]=> NULL ["source"]=> string(17) "giaoducthoidai.vn" ["publication_date"]=> string(10) "2024-09-15" ["categories"]=> array(2) { [0]=> string(17) "Academic Research" [1]=> string(11) "Competition" } } [6]=> array(7) { ["title_en"]=> string(80) "MARTYR PROF. DR. INTERNATIONAL SUCCESS FROM İLHAN VARANK SCIENCE AND ART CENTER" ["snippet_en"]=> string(212) "Martyr Prof. Dr. Students of İlhan Varank Science and Art Center came third in the competition organized by TÜBİTAK and were entitled to represent our country in the international "Regeneron ISEF" competition." ["url"]=> string(141) "https://balikesirbirlikgazetesi.com/bilim-ve-teknoloji/sehit-prof-dr-ilhan-varank-bilim-ve-sanat-merkezi-nden-uluslararasi-basari-117997.html" ["image_url"]=> NULL ["source"]=> string(27) "balikesirbirlikgazetesi.com" ["publication_date"]=> string(10) "2024-09-13" ["categories"]=> array(4) { [0]=> string(17) "Academic Research" [1]=> string(21) "Competitive Behaviour" [2]=> string(5) "Event" [3]=> string(11) "Competition" } } [7]=> array(7) { ["title_en"]=> string(82) "Regeneron’s Libtayo shows durable survival benefits in phase 3 lung cancer study" ["snippet_en"]=> string(74) "Non-small cell lung cancer accounts for up to 85% of all lung cancer cases" ["url"]=> string(115) "https://www.pmlive.com/pharma_news/regenerons-libtayo-shows-durable-survival-benefits-in-phase-3-lung-cancer-study/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/955af032-8d3b-4e6f-af13-84a08ffaff51" ["source"]=> string(10) "pmlive.com" ["publication_date"]=> string(10) "2024-09-11" ["categories"]=> array(1) { [0]=> string(17) "Academic Research" } } [8]=> array(7) { ["title_en"]=> string(183) "Press release: Dupixent is the first and only biologic agent to achieve significant improvements in disease remission and symptoms in pivotal study of patients with bullous pemphigoid" ["snippet_en"]=> string(219) "Dupixent is the first and only biologic agent to achieve significant improvements in disease remission and symptoms in pivotal study of patients with bullous pemphigoid Study met primary endpoints and all endpoints main" ["url"]=> string(198) "https://www.actusante.net/pr/communique-de-presse-dupixent-est-le-premier-et-le-seul-agent-biologique-a-obtenir-des-ameliorations-significatives-de-la-remission-de-la-maladie-et-des-symptomes-dans-l" ["image_url"]=> NULL ["source"]=> string(13) "actusante.net" ["publication_date"]=> string(10) "2024-09-11" ["categories"]=> array(2) { [0]=> string(17) "Academic Research" [1]=> string(12) "Board Change" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(263) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(116) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(61) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(59) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(43) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(32) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc